

Market Applicability							
Market	DC	GA	KY	MD	NJ	NY	WA
Applicable	X	X	X	X	X	X	X

Gonadotropin Releasing Hormone Analogs (GnRH)

Override(s)	Approval Duration
Prior Authorization Quantity Limit	Varies upon diagnosis

Medications	Quantity Limit	Line of Business
Eligard (leuprolide acetate) 7.5mg	1 per 4 weeks	All MCD
Eligard (leuprolide acetate) 22.5mg	1 per 12 weeks	All MCD
Eligard (leuprolide acetate) 30mg	1 per 16 weeks	All MCD
Eligard (leuprolide acetate) 45mg	1 per 24 weeks	All MCD
Fensolvi (leuprolide acetate) 45 mg kit	1 per 24 weeks	All MCD
Firmagon (degarelix) 80mg	1 injection (80 mg) per 28 days	VA MCD and AGP MCD Only
Firmagon (degarelix) 120mg	2 injections (240 mg) per year	VA MCD and AGP MCD Only
Lupaneta Pack (leuprolide acetate and norethindrone acetate)	N/A	VA MCD and AGP MCD Only
Leuprolide acetate (immediate release)	N/A	All MCD
Lupron Depot (1 month) (leuprolide acetate) 3.75mg	1 per 4 weeks	VA MCD and AGP MCD Only
Lupron Depot (1 month) (leuprolide acetate) 7.5 mg	1 per 4 weeks	VA MCD and AGP MCD Only
Lupron Depot (3 months) (leuprolide acetate) 11.25mg and 22.5mg	1 kit per 12 weeks	VA MCD and AGP MCD Only
Lupron Depot (4 month) (leuprolide acetate) 30mg	1 per 16 weeks	VA MCD and AGP MCD Only
Lupron Depot (6 month) (leuprolide acetate) 45mg	1 per 24 weeks	VA MCD and AGP MCD Only
Lupron Depot Ped (leuprolide acetate) 7.5mg	1 per 4 weeks	VA MCD and AGP MCD Only
Lupron Depot Ped (leuprolide acetate) 11.25mg	N/A	VA MCD and AGP MCD Only
Lupron Depot Ped (leuprolide acetate) 15mg	N/A	VA MCD and AGP MCD Only

Market Applicability							
Market	DC	GA	KY	MD	NJ	NY	WA
Applicable	X	X	X	X	X	X	X

Lupron Depot Ped (3 month) (leuprolide acetate) 11.25mg	1 kit per 12 weeks	VA MCD and AGP MCD Only
Lupron Depot Ped (3 month) (leuprolide acetate) 30mg	N/A	VA MCD and AGP MCD Only
Supprelin LA (histrelin acetate) 50mg Implant	1 per year	VA MCD and AGP MCD Only
Synarel Nasal Spray (nafarelin acetate) 2mg/mL (60 sprays/bottle)	5 bottles per 30 days	All MCD
Trelstar (triptorelin pamoate) 22.5mg	1 per 24 weeks	VA MCD and AGP MCD Only
Trelstar Depot (triptorelin pamoate) 3.75mg	1 per 4 weeks	VA MCD and AGP MCD Only
Trelstar LA (triptorelin pamoate) 11.25mg	1 per 12 weeks	VA MCD and AGP MCD Only
Triptodur (triptorelin pamoate extended release) 22.5mg kit	1 kit per 24 weeks	VA MCD and AGP MCD Only
Vantas Implant (histrelin acetate)	1 per year	VA MCD and AGP MCD Only
Zoladex (1 month) (goserelin acetate) 3.6mg implant	1 per 4 weeks	VA MCD and AGP MCD Only
Zoladex (3 month) (goserelin acetate) 10.8mg implant	1 per 12 weeks	VA MCD and AGP MCD Only

APPROVAL CRITERIA

I. Breast Cancer –Goserelin acetate or leuprolide acetate (Lupron Depot 3.75 mg)

Goserelin acetate or leuprolide acetate (Lupron Depot 3.75 mg) **may be approved** for the treatment of men and pre- or peri- menopausal women with hormone receptor positive breast cancer.

Goserelin acetate or leuprolide acetate **may NOT be approved** for the treatment of breast cancer when the criteria above are not met.

II. Ovarian Cancer (including fallopian tube cancer and primary peritoneal cancer)– Leuprolide acetate (Lupron Depot 3.75 mg, Lupron Depot-3 Month 11.25 mg)

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

Market Applicability							
Market	DC	GA	KY	MD	NJ	NY	WA
Applicable	X	X	X	X	X	X	X

Leuprolide acetate (Lupron Depot 3.75 mg, Lupron Depot-3 Month 11.25 mg) **may be approved** for ovarian cancer when **any** of the following are met:

- A. Hormonal therapy for clinical relapse in individuals with stage II-IV granulosa cell tumors; **OR**
- B. Hormonal therapy for treatment of epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer as a single agent for persistent disease or recurrence.

Leuprolide acetate **may NOT be approved** for ovarian cancer when the criteria above are not met.

III. **Prostate Cancer- Degarelix; goserelin acetate; histrelin acetate (Vantas); leuprolide acetate (Eligard 7.5 mg [1 Month], 22.5 mg [3 Month], 30 mg [4 month], 45 mg [6 Month]; Lupron Depot 7.5 mg [1 Month], 22.5 mg [3 Month], 30 mg [4 Month], 45 mg [6 Month]), or triptorelin pamoate**

- A. Degarelix; goserelin acetate; histrelin acetate (Vantas); leuprolide acetate, **or** (Eligard 7.5 mg [1 Month], 22.5 mg [3 Month], 30 mg [4 Month], 45 mg [6 Month]; Lupron Depot 7.5 mg [1 Month], 22.5 mg [3 Month], 30 mg [4 Month], 45 mg [6 Month]); triptorelin pamoate **may be approved** for the treatment of prostate cancer when **any** of the following indications are met:
 1. Used as androgen deprivation therapy as a single agent or in combination with an antiandrogen; **OR**
 2. Used for clinically localized disease* with intermediate (T2b to T2c cancer, Gleason score of 7/Gleason grade group 2-3, or prostate specific antigen (PSA) value of 10-20 ng/ml) or higher risk of recurrence as neoadjuvant therapy with radiation therapy or cryosurgery; **OR**
 3. Used for progressive castration-naïve disease; **OR**
 4. Used for castration-recurrent disease; **OR**
 5. Other advanced*, recurrent, or metastatic disease*.

*Definitions –

- Clinically localized prostate cancer: Cancer presumed to be confined within the prostate based on pre-treatment findings such as physical exam, imaging, and biopsy findings.
- Locally advanced disease (prostate cancer): Cancer that has spread from where it started to nearby tissue or lymph nodes.
- Metastatic: The spread of cancer from one part of the body to another; a metastatic tumor contains cells that are like those in the original (primary) tumor and have spread.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

Market Applicability							
Market	DC	GA	KY	MD	NJ	NY	WA
Applicable	X	X	X	X	X	X	X

- Advanced prostate cancer: Disease that has spread beyond the prostate to surrounding tissues or distant organs.

Degarelix, goserelin acetate, histrelin acetate (Vantas), leuprolide acetate, or triptorelin pamoate **may NOT be approved** for treatment of prostate cancer when the criteria above are not met.

IV. **Central Precocious Puberty- Leuprolide acetate (Fensolvi, Lupron Depot-Ped), nafarelin acetate (Synarel Nasal Spray), histrelin acetate subcutaneous implant (Supprelin LA), triptorelin pamoate intramuscular extended release (Triptodur)**

- A. Leuprolide acetate (Fensolvi, Lupron Depot-Ped), nafarelin acetate (Synarel Nasal Spray), histrelin acetate subcutaneous implant (Supprelin LA), and triptorelin IM (Triptodur) **may be approved** for individuals with a diagnosis of central precocious puberty (defined as the beginning of secondary sexual characteristics before age 8 in girls and 9 in boys) (Kaplowitz, et al. 2016); **AND**
- B. If individual is using Triptodur (triptorelin pamoate), IM injection is given every 6 months for those 2 years of age or older.

V. **Gynecology Uses- Goserelin acetate, leuprolide acetate, leuprolide acetate for depot suspension and norethindrone (Lupaneta Pack), or nafarelin acetate**

- A. Goserelin acetate, leuprolide acetate, or nafarelin acetate **may be approved** the following criteria are met:
 1. Individual has a diagnosis of chronic pelvic pain* (defined as noncyclical pain lasting 6 or more months that localizes to the anatomic pelvis, anterior abdominal wall at or below the umbilicus, the lumbosacral back, or the buttocks, and is of sufficient severity to cause functional disability or lead to medical care [ACOG, 2004])-*not to continue beyond 3 months if there is no symptomatic relief; **OR**
 2. Individual is using to induce amenorrhea (including, but not limited to menstruating women diagnosed with severe thrombocytopenia or aplastic anemia).
- B. Goserelin acetate **may be approved** if the following criteria are met:
 1. Individual is using for treatment of endometriosis and duration of treatment limited to 6 months; **OR**
 2. Individual is using for dysfunctional uterine bleeding; **OR**
 3. Individual is using for endometrial thinning prior to endometrial ablation for dysfunctional uterine bleeding (3.6 mg implant only).

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

Market Applicability							
Market	DC	GA	KY	MD	NJ	NY	WA
Applicable	X	X	X	X	X	X	X

- C. Leuprolide acetate **may be approved** if the following criteria are met:
1. Individual is using for initial treatment or retreatment of endometriosis (Initial treatment duration: 6 months; Retreatment duration: a single course for 6 months. Total duration of therapy should not exceed 12 months); **OR**
 2. Individual is using for preoperative treatment as adjunct to surgical treatment of uterine fibroids (leiomyoma uteri), including but not limited to reducing the size of fibroids to allow for a vaginal procedure (AHFS); **OR**
 3. Individual is using prior to surgical treatment (myomectomy or hysterectomy) in those with a diagnosis of confirmed anemia (Letheby et.al. 2001).
- D. Leuprolide acetate for depot suspension and norethindrone acetate tablets (Lupaneta Pack) **may be approved** if the following criteria are met:
1. Individual is using for initial treatment or retreatment of endometriosis (Initial treatment duration: 6 months; Retreatment duration: a single course for 6 months. Total duration of therapy should not exceed 12 months).
- E. Nafarelin acetate **may be approved** if the following criteria are met:
1. Individual is using for endometriosis; **AND**
 2. Duration of treatment limited to 6 months.

VI. Ovarian Preservation for Fertility during Chemotherapy

- A. GnRH analogs **may be approved** for preservation of fertility in pre-menopausal women that will receive chemotherapy with curative intent.

GnRH analogs **may NOT be approved** for preservation of fertility when the criteria above are not met.

VII. Gender Dysphoria/Incongruence in Adolescents

- A. GnRH analogs **may be approved** for adolescents (greater than or equal to 10 years of age and less than 18 years of age) with gender dysphoria (Hembree 2009, 2017) when **all** of the following criteria are met:
1. Fulfills the DSM V criteria for gender dysphoria (Hembree 2009, 2017); **AND**

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

Market Applicability							
Market	DC	GA	KY	MD	NJ	NY	WA
Applicable	X	X	X	X	X	X	X

2. Has experienced puberty to at least Tanner stage 2 (Hembree 2009, 2017); **AND**
3. Has (early) pubertal changes that have resulted in an increase of their gender dysphoria (Hembree 2009, 2017); **AND**
4. Does not suffer from a psychiatric comorbidity that interferes with the diagnostic work-up or treatment (Hembree 2009, 2017); **AND**
5. Has psychological and social support during treatment (Hembree 2009, 2017); **AND**
6. Demonstrates knowledge and understanding of the expected outcomes of GnRH analog treatment (Hembree 2009, 2017).

GnRH analogs **may NOT be approved** for adolescents with gender dysphoria when the criteria above are not met.

VIII. Salivary Gland Tumors – Leuprolide acetate (Eligard 7.5 mg [1 Month], 22.5 mg [3 Month]; Lupron Depot 7.5 mg [1 Month], 22.5 mg [3 Month])

- A. Leuprolide acetate (Eligard 7.5 mg [1 Month], 22.5 mg [3 Month]; Lupron Depot 7.5 mg [1 Month], 22.5 mg [3 Month]) **may be approved** for the treatment of salivary gland tumors when all of the following criteria are met:
 1. Used for androgen receptor positive recurrent disease with distant metastases; **AND**
 2. Individual has a current Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0-3.

Leuprolide acetate **may NOT be approved** for the treatment of salivary gland tumors when the criteria above are not met.

Key References:

1. Balbi G, Piano LD, Cardone A, Cirelli G. Second-line therapy of advanced ovarian cancer with GnRH analogs. Int J Gynecol Cancer. 2004; 14(5):799-803.
2. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.: 2019. URL: <http://www.clinicalpharmacology.com>. Updated periodically.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

Market Applicability							
Market	DC	GA	KY	MD	NJ	NY	WA
Applicable	X	X	X	X	X	X	X

3. Dalin MG, Watson PA, Ho AL, Morris LG. Androgen receptor signaling in salivary gland cancer. *Cancers*. 2017; 9(2)pii:E17.
4. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: April 17, 2019.
5. Del Mastro L, Boni L, Michelotti A, et al. Effect of the gonadotropin-releasing hormone analogue triptorelin on the occurrence of chemotherapy-induced early menopause in premenopausal women with breast cancer: a randomized trial. *JAMA*. 2011; 306(3):269-276.
6. Del Mastro L, Ceppi M, Poggio F, et al. Gonadotropin-releasing hormone analogues for the prevention of chemotherapy-induced premature ovarian failure in cancer women: systematic review and meta-analysis of randomized trials. *Cancer Treat Rev*. 2014; 40(5):675-683.
7. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.
8. Elgindy EA, El-Haieg DO, Khorshid OM, et al. Gonadotrophin suppression to prevent chemotherapy-induced ovarian damage: a randomized controlled trial. *Obstet Gynecol*. 2013; 121(1):78-86.
9. Fishman A, Kudelka AP, Tresukosol D, et al. Leuprolide acetate for treating refractory or persistent ovarian granulosa cell tumor. *J Reprod Med*. 1996; 41(6):393-396.
10. Fushimi C, Tada Y, Takahashi H, et al. A prospective phase II study of combined androgen blockade in patients with androgen receptor-positive metastatic or locally advanced unresectable salivary gland carcinoma. *Ann Oncol*. 2017 Dec 1; [Epub ahead of print]. Available at: <https://www.ncbi.nlm.nih.gov/pubmed/29211833>. Accessed on April 5, 2018.
11. Gerber B, von Minckwitz G, Stehle H, et al.; German Breast Group Investigators. Effect of luteinizing hormone-releasing hormone agonist on ovarian function after modern adjuvant breast cancer chemotherapy: the GBG 37 ZORO study. *J Clin Oncol*. 2011; 29(17):2334-2341.
12. Giordano SH, Buzdar AU, Hortobagyi GN. Breast cancer in men. *Ann Intern Med*. 2002; 137(8):678-687.
13. Hotko YS. Male breast cancer: clinical presentation, diagnosis, treatment. *Exp Oncol*. 2013; 35(4):303-310.
14. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2019; Updated periodically.
15. Moore HC, Unger JM, Phillips KA, et al; POEMS/S0230 Investigators. Goserelin for ovarian protection during breast-cancer adjuvant chemotherapy. *N Engl J Med*. 2015; 372(10):923-932.
16. NCCN Clinical Practice Guidelines in Oncology™. © 2019 National Comprehensive Cancer Network, Inc. For additional information visit the NCCN website: <http://www.nccn.org/index.asp>. Accessed on October 14, 2019.
 - a. Adolescent and Young Adult Oncology V1.2020. Revised July 11, 2019.
 - b. Breast Cancer. V3.2019. Revised March 14, 2019.
 - c. Head and Neck Cancers. V3.2019. Revised September 16, 2019.
 - d. Ovarian Cancer. V2.2019. Revised September 17, 2019.
 - e. Prostate Cancer. V4.2019. Revised August 19, 2019.
17. Pagani O, Regan MM, Walley BA, et al.; TEXT and SOFT Investigators; International Breast Cancer Study Group. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. *N Engl J Med*. 2014; 371(2):107-118.
18. Rao GG, Miller DS. Hormonal therapy in epithelial ovarian cancer. *Expert RevAnticancer Ther*. 2006; 6(1):43-47.
19. Sverrisdottir A, Nystedt M, Johansson H, Fornander T. Adjuvant goserelin and ovarian preservation in chemotherapy treated patients with early breast cancer: results from a randomized trial. *Breast Cancer Res Treat*. 2009; 117(3):561-570.
20. Vitek WS, Shayne M, Hoeger K, et al. Gonadotropin-releasing hormone agonists for the preservation of ovarian function among women with breast cancer who did not use tamoxifen after chemotherapy: a systematic review and meta-analysis. *Fertil Steril*. 2014; 102(3):808-815.
21. Wilt TJ, MacDonald R, Rutks I, et al. Systematic review: comparative effectiveness and harms of treatments for clinically localized prostate cancer. *Ann Intern Med*. 2008; 148(6):435-448.
22. Yokoyama Y, Mizunuma H. Recurrent epithelial ovarian cancer and hormone therapy. *World J Clin Cases*. 2013; 1(6):187-190.
23. American College of Obstetrics and Gynecology Committee on Practice Bulletins -- Gynecology. ACOG Practice Bulletin No. 51. Chronic pelvic pain. *Obstet Gynecol*. 2004 (reaffirmed 2008); 103(3):589-605.
24. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. 2013. Washington, DC. Pages 451-459.
25. Clinical Pharmacology [database online]. Tampa, FL: Gold Standard, Inc.; 2019. URL: <http://www.clinicalpharmacology.com>. Updated periodically.
26. DailyMed. Package inserts. U.S. National Library of Medicine, National Institutes of Health website. <http://dailymed.nlm.nih.gov/dailymed/about.cfm>. Accessed: June 8, 2019.
27. DrugPoints® System [electronic version]. Truven Health Analytics, Greenwood Village, CO. Updated periodically.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.

Market Applicability							
Market	DC	GA	KY	MD	NJ	NY	WA
Applicable	X	X	X	X	X	X	X

28. Hembree WC, Cohen-Kettenis P, Delemarre-van de Waal HA, et al.; Endocrine Society. Endocrine treatment of transsexual persons: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2009; 94(9):3132-3154.
29. Hembree WC, Cohen-Kettenis P, Gooren L, et al.; Endocrine Society. Endocrine Treatment of Gender Dysphoric/Gender Incongruent Persons. An Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2017; 102(11):1–35.
30. Kaplowitz P, Bloch C, the SECTION ON ENDOCRINOLOGY. Evaluation and Referral of Children With Signs of Early Puberty. Pediatrics. 2016;137(1):e20153732
31. Lethaby A, Vollenhoven B, Sowter M. Pre-operative GnRH analogue therapy before hysterectomy or myomectomy for uterine fibroids. Cochrane Database Syst Rev. 2001; (2):CD000547.
32. Lexi-Comp ONLINE™ with AHFS™, Hudson, Ohio: Lexi-Comp, Inc.; 2019; Updated periodically.
33. Nebesio TD, Eugster EA. Current concepts in normal and abnormal puberty. Curr Probl Pediatr Adolesc Health Care. 2007;37(2):50–72. doi: 10.1016/j.cppeds.2006.10.005.

Federal and state laws or requirements, contract language, and Plan utilization management programs or policies may take precedence over the application of this clinical criteria.

No part of this publication may be reproduced, stored in a retrieval system or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from the health plan.

This policy does not apply to health plans or member categories that do not have pharmacy benefits, nor does it apply to Medicare. Note that market specific restrictions or transition-of-care benefit limitations may apply.